Synopsis
Synopsis
0
JDMF
0
VMF
0
API
0
Australia
0
South Africa
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Finished Drug Prices
NA
1. 232632, Bms
2. 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic Acid Dimethyl Ester
3. Atazanavir
4. Bms 232632
5. Bms 232632 05
6. Bms-232632
7. Bms-232632-05
8. Bms232632
9. Bms23263205
10. Cgp 73547
11. Cgp 75136
12. Cgp 75176
13. Cgp 75355
14. Cgp-73547
15. Cgp-75136
16. Cgp-75176
17. Cgp-75355
18. Cgp73547
19. Cgp75136
20. Cgp75176
21. Cgp75355
22. Reyataz
1. 229975-97-7
2. Reyataz
3. Atazanavir Sulphate
4. Bms-232632-05
5. Atazanavir (sulfate)
6. Atazanavir Sulfate [usan]
7. Atazor
8. Atazanavir So4
9. 4mt4vie29p
10. Atazanavir Sulfate (bms-232632-05)
11. 229975-97-7 (sulfate)
12. Nsc-742546
13. 2,5,6,10,13-pentaazatetradecanedioic Acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, Dimethyl Ester, (3s,8s,9s,12s)-, Sulfate (1:1) (salt)
14. Reyataz (tn)
15. 2,5,6,10,13-pentaazatetradecanedioic Acid, 3-12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((-4-(2-pyridinyl)phenyl)methyl)-, Dimethyl Ester, (3s,8s,9s,12s)-, Sulfate (1:1) (salt)
16. Dimethyl (3s,8s,9s,12s)-9-benzyl-3,12,di-tert-butyl-8-hydroxy-4,11-dioxo-6-(p-2-pyridylbenzyl)-2,5,6,10,13-pentaazatetradecanedioate, Sulfate (1:1) (salt)
17. Chebi:31243
18. Smr002544693
19. Atazanavir Bisulfate Salt
20. Unii-4mt4vie29p
21. Ulfuric Acid
22. Atazanaviri Sulfas
23. Mls003915641
24. Mls006010199
25. Schembl341700
26. Atazanavir So4 [vandf]
27. Atazanavir Sulfate [mi]
28. Atazanavir Sulfate (jan/usan)
29. Atazanavir Sulfate [jan]
30. Chembl1200678
31. Bms-232632-05, Reyataz
32. Dtxsid401017206
33. Atazanavir Sulfate [mart.]
34. Amy36999
35. Atazanavir Sulfate [usp-rs]
36. Atazanavir Sulfate [who-dd]
37. Atazanavir Sulfate [who-ip]
38. Ex-a4010
39. Methyl N-[(2s)-1-[2-[(2s,3s)-2-hydroxy-3-[[(2s)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate;sulfuric Acid
40. Hy-17367a
41. Mfcd08067748
42. S1457
43. Akos016000176
44. Atazanavir Sulphate [ema Epar]
45. Ccg-270493
46. Cs-1890
47. Nsc 742546
48. Atazanavir Sulfate [orange Book]
49. Atazanavir Sulfate [ep Monograph]
50. As-14954
51. Atazanaviri Sulfas [who-ip Latin]
52. Evotaz Component Atazanavir Sulfate
53. Methyl ((5s,10s,11s,14s)-11-benzyl-5-(tert-butyl)-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-(4-(pyridin-2-yl)benzyl)-2-oxa-4,7,8,12-tetraazahexadecan-14-yl)carbamate Sulfate
54. Atazanavir Sulfate Component Of Evotaz
55. Sw220258-1
56. D01276
57. 975a977
58. A816475
59. J-014934
60. 3-amino-3-(3-benzyloxy-phenyl)-propionicacid
61. Q27114238
62. 2,5,6,10,13-pentaazatetradecanedioic Acid, 3-12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((-4-(2-pyridinyl)phenyl)methyl)-, Dimethyl Ester, (3s,8s,9s,12s)-, Sulphate (1:1) (salt)
63. Dimethyl (3s,8s,9s,12s)-9-benzyl-3,12,di-tert-butyl-8-hydroxy-4,11-dioxo-6-(p-2-pyridylbenzyl)-2,5,6,10,13-pentaazatetradecanedioate, Sulphate (1:1) (salt)
64. Dimethyl (3s,8s,9s,12s)-9-benzyl-3,12-di-tert-butyl-8-hydroxy-4,11-dioxo-6-((4-(pyridin-2-yl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioate Monosulfate
65. Methyl N-[(1s)-1-[[(1s,2s)-1-benzyl-2-hydroxy-3-[[[(2s)-2-(methoxycarbonylamino)-3,3-dimethyl-butanoyl]amino]-[(4-phenylphenyl)methyl]amino]propyl]carbamoyl]-2,2-dimethyl-propyl]carbamate; Sulfuric Acid;atazanavir Sulfate
66. Methyl N-[(2s)-1-[2-[(2s,3s)-2-hydroxy-3-[[(2s)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate;s
Molecular Weight | 802.9 g/mol |
---|---|
Molecular Formula | C38H54N6O11S |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 13 |
Rotatable Bond Count | 18 |
Exact Mass | 802.35712773 g/mol |
Monoisotopic Mass | 802.35712773 g/mol |
Topological Polar Surface Area | 254 Ų |
Heavy Atom Count | 56 |
Formal Charge | 0 |
Complexity | 1190 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Atazanavir sulfate |
Drug Label | REYATAZ (atazanavir sulfate) is an azapeptide inhibitor of HIV-1 protease.The chemical name for atazanavir sulfate is (3S,8S,9S,12S)-3,12-Bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pen... |
Active Ingredient | Atazanavir sulfate |
Dosage Form | Capsule |
Route | oral; Oral |
Strength | 300mg; eq 100mg base; 200mg; eq 200mg base; 100mg; eq 300mg base; 150mg; eq 150mg base |
Market Status | Tentative Approval; Prescription |
Company | Matrix Labs; Emcure Pharms; Aurobindo Pharma; Teva Pharms Usa; Emcure Pharma |
2 of 4 | |
---|---|
Drug Name | Reyataz |
PubMed Health | Atazanavir (By mouth) |
Drug Classes | Antiretroviral Agent, Antiviral |
Drug Label | REYATAZ (atazanavir sulfate) is an azapeptide inhibitor of HIV-1 protease.The chemical name for atazanavir sulfate is (3S,8S,9S,12S)-3,12-Bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pen... |
Active Ingredient | Atazanavir sulfate |
Dosage Form | Capsule; Powder |
Route | Oral |
Strength | eq 50mg base/packet; eq 150mg base; eq 200mg base; eq 300mg base |
Market Status | Prescription |
Company | Bristol Myers Squibb |
3 of 4 | |
---|---|
Drug Name | Atazanavir sulfate |
Drug Label | REYATAZ (atazanavir sulfate) is an azapeptide inhibitor of HIV-1 protease.The chemical name for atazanavir sulfate is (3S,8S,9S,12S)-3,12-Bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pen... |
Active Ingredient | Atazanavir sulfate |
Dosage Form | Capsule |
Route | oral; Oral |
Strength | 300mg; eq 100mg base; 200mg; eq 200mg base; 100mg; eq 300mg base; 150mg; eq 150mg base |
Market Status | Tentative Approval; Prescription |
Company | Matrix Labs; Emcure Pharms; Aurobindo Pharma; Teva Pharms Usa; Emcure Pharma |
4 of 4 | |
---|---|
Drug Name | Reyataz |
PubMed Health | Atazanavir (By mouth) |
Drug Classes | Antiretroviral Agent, Antiviral |
Drug Label | REYATAZ (atazanavir sulfate) is an azapeptide inhibitor of HIV-1 protease.The chemical name for atazanavir sulfate is (3S,8S,9S,12S)-3,12-Bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pen... |
Active Ingredient | Atazanavir sulfate |
Dosage Form | Capsule; Powder |
Route | Oral |
Strength | eq 50mg base/packet; eq 150mg base; eq 200mg base; eq 300mg base |
Market Status | Prescription |
Company | Bristol Myers Squibb |
Reyataz capsules, co-administered with low dose ritonavir, are indicated for the treatment of HIV-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products (see section 4. 2).
Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors ( 4 PI mutations).
The choice of Reyataz in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patients treatment history (see sections 4. 4 and 5. 1).
Reyataz oral powder, co-administered with low dose ritonavir, is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected paediatric patients at least 3 months of age and weighing at least 5 kg (see section 4. 2).
Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors ( 4 PI mutations). The choice of Reyataz in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patients treatment history (see sections 4. 4 and 5. 1).
HIV Protease Inhibitors
Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. (See all compounds classified as HIV Protease Inhibitors.)
J05AE08
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Atazanavir Sulfate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Atazanavir Sulfate, including repackagers and relabelers. The FDA regulates Atazanavir Sulfate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Atazanavir Sulfate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Atazanavir Sulfate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Atazanavir Sulfate supplier is an individual or a company that provides Atazanavir Sulfate active pharmaceutical ingredient (API) or Atazanavir Sulfate finished formulations upon request. The Atazanavir Sulfate suppliers may include Atazanavir Sulfate API manufacturers, exporters, distributors and traders.
click here to find a list of Atazanavir Sulfate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Atazanavir Sulfate DMF (Drug Master File) is a document detailing the whole manufacturing process of Atazanavir Sulfate active pharmaceutical ingredient (API) in detail. Different forms of Atazanavir Sulfate DMFs exist exist since differing nations have different regulations, such as Atazanavir Sulfate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Atazanavir Sulfate DMF submitted to regulatory agencies in the US is known as a USDMF. Atazanavir Sulfate USDMF includes data on Atazanavir Sulfate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Atazanavir Sulfate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Atazanavir Sulfate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Atazanavir Sulfate Drug Master File in Korea (Atazanavir Sulfate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Atazanavir Sulfate. The MFDS reviews the Atazanavir Sulfate KDMF as part of the drug registration process and uses the information provided in the Atazanavir Sulfate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Atazanavir Sulfate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Atazanavir Sulfate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Atazanavir Sulfate suppliers with KDMF on PharmaCompass.
A Atazanavir Sulfate CEP of the European Pharmacopoeia monograph is often referred to as a Atazanavir Sulfate Certificate of Suitability (COS). The purpose of a Atazanavir Sulfate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Atazanavir Sulfate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Atazanavir Sulfate to their clients by showing that a Atazanavir Sulfate CEP has been issued for it. The manufacturer submits a Atazanavir Sulfate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Atazanavir Sulfate CEP holder for the record. Additionally, the data presented in the Atazanavir Sulfate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Atazanavir Sulfate DMF.
A Atazanavir Sulfate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Atazanavir Sulfate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Atazanavir Sulfate suppliers with CEP (COS) on PharmaCompass.
A Atazanavir Sulfate written confirmation (Atazanavir Sulfate WC) is an official document issued by a regulatory agency to a Atazanavir Sulfate manufacturer, verifying that the manufacturing facility of a Atazanavir Sulfate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Atazanavir Sulfate APIs or Atazanavir Sulfate finished pharmaceutical products to another nation, regulatory agencies frequently require a Atazanavir Sulfate WC (written confirmation) as part of the regulatory process.
click here to find a list of Atazanavir Sulfate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Atazanavir Sulfate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Atazanavir Sulfate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Atazanavir Sulfate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Atazanavir Sulfate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Atazanavir Sulfate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Atazanavir Sulfate suppliers with NDC on PharmaCompass.
Atazanavir Sulfate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Atazanavir Sulfate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Atazanavir Sulfate GMP manufacturer or Atazanavir Sulfate GMP API supplier for your needs.
A Atazanavir Sulfate CoA (Certificate of Analysis) is a formal document that attests to Atazanavir Sulfate's compliance with Atazanavir Sulfate specifications and serves as a tool for batch-level quality control.
Atazanavir Sulfate CoA mostly includes findings from lab analyses of a specific batch. For each Atazanavir Sulfate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Atazanavir Sulfate may be tested according to a variety of international standards, such as European Pharmacopoeia (Atazanavir Sulfate EP), Atazanavir Sulfate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Atazanavir Sulfate USP).
LOOKING FOR A SUPPLIER?